Clinical Trial Results:
An Open-label, Randomized, Crossover, Reader-blinded Study To Investigate the Effect of Prucalopride and Polyethylene Glycol 3350 on Colon Motility with Intraluminal Manometry in Subjects with Chronic Constipation
Summary
|
|
EudraCT number |
2012-002495-13 |
Trial protocol |
BE |
Global end of trial date |
27 Nov 2013
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Sep 2018
|
First version publication date |
13 Mar 2015
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
SPD555-403
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01707667 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Shire Movetis NV
|
||
Sponsor organisation address |
Veedijk 58(104), Turnhout, Belgium, 2300
|
||
Public contact |
Medical Communications, Shire-Movetis, 0032 14404390, shire-movetis.clinicaltrials@shire.com
|
||
Scientific contact |
Medical Communications, Shire-Movetis, 0032 14404390, shire-movetis.clinicaltrials@shire.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
27 Nov 2013
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
27 Nov 2013
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To evaluate differences in pharmacodynamic effects of prucalopride and polyethylene glycol (PEG 3350) + electrolytes on the number of colonic high amplitude propagating contractions (HAPC) during a 12-hour intraluminal manometry in chronically constipated subjects.
|
||
Protection of trial subjects |
The subject's informed consent was a mandatory condition for taking part in the study. It was obtained in writing prior to the performance of any study-specific procedures. This study was conducted in accordance with International Conference on Harmonisation of Good Clinical Practice, the principles of the Declaration of Helsinki, as well as other applicable local ethical and legal requirements.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
27 Feb 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United States: 13
|
||
Worldwide total number of subjects |
13
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
13
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
The study was conducted in 1 center (United States). | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
Subjects were screened and entered a 10- to 19-day run in period, during which they recorded their bowel habits and rescue medication use in a daily diary and the existence of constipation was confirmed. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Treatment Period 1
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Not blinded | |||||||||||||||
Blinding implementation details |
To minimize bias, the study was reader-blinded: the tracings were read by an experienced gastroenterologist who received de-identified recordings that did not specify which treatment the subject had received.
|
|||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Prucalopride-Polyethylene glycol (PEG) | |||||||||||||||
Arm description |
A single dose of prucalopride in the first period followed by 2 doses of PEG 3350 plus electrolytes in the second period. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Prucalopride
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Resolor
|
|||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
One 2mg tablet administered with 125ml of water on Day 1
|
|||||||||||||||
Arm title
|
Polyethylene glycol (PEG)-Prucalopride | |||||||||||||||
Arm description |
Two doses of PEG 3350 plus electrolytes in the first period followed by a single dose of prucalopride in the second period. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Polyethylene glycol (PEG) 3350
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Movicol
|
|||||||||||||||
Pharmaceutical forms |
Powder for oral solution
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
13.8g-sachets of PEG 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water (125ml). Administered twice on Day 1 (once in the morning and once prior to lunch).
|
|||||||||||||||
|
||||||||||||||||
Period 2
|
||||||||||||||||
Period 2 title |
Treatment Period 2
|
|||||||||||||||
Is this the baseline period? |
No | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Not blinded | |||||||||||||||
Blinding implementation details |
To minimize bias, the study was reader-blinded: the tracings were read by an experienced gastroenterologist who received de-identified recordings that did not specify which treatment the subject had received.
|
|||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Prucalopride-Polyethylene glycol (PEG) | |||||||||||||||
Arm description |
A single dose of prucalopride in the first period followed by 2 doses of PEG 3350 plus electrolytes in the second period. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Polyethylene glycol (PEG) 3350
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Movicol
|
|||||||||||||||
Pharmaceutical forms |
Powder for oral solution
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
13.8g-sachets of PEG 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water (125ml). Administered twice on Day 1 (once in the morning and once prior to lunch).
|
|||||||||||||||
Arm title
|
Polyethylene glycol (PEG)-Prucalopride | |||||||||||||||
Arm description |
Two doses of PEG 3350 plus electrolytes in the first period followed by a single dose of prucalopride in the second period. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Prucalopride
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Resolor
|
|||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
One 2mg tablet administered with 125ml of water on Day 1
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Prucalopride-Polyethylene glycol (PEG)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
A single dose of prucalopride in the first period followed by 2 doses of PEG 3350 plus electrolytes in the second period. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Polyethylene glycol (PEG)-Prucalopride
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Two doses of PEG 3350 plus electrolytes in the first period followed by a single dose of prucalopride in the second period. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Prucalopride-Polyethylene glycol (PEG)
|
||
Reporting group description |
A single dose of prucalopride in the first period followed by 2 doses of PEG 3350 plus electrolytes in the second period. | ||
Reporting group title |
Polyethylene glycol (PEG)-Prucalopride
|
||
Reporting group description |
Two doses of PEG 3350 plus electrolytes in the first period followed by a single dose of prucalopride in the second period. | ||
Reporting group title |
Prucalopride-Polyethylene glycol (PEG)
|
||
Reporting group description |
A single dose of prucalopride in the first period followed by 2 doses of PEG 3350 plus electrolytes in the second period. | ||
Reporting group title |
Polyethylene glycol (PEG)-Prucalopride
|
||
Reporting group description |
Two doses of PEG 3350 plus electrolytes in the first period followed by a single dose of prucalopride in the second period. | ||
Subject analysis set title |
Prucalopride
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
A single dose of 2mg prucalopride, administered orally as tablets with 125mL of water on Day 1.
|
||
Subject analysis set title |
PEG 3350
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1 (once in the morning and once prior to lunch).
|
|
|||||||||||||
End point title |
The Number of High-Amplitude Propagating Contractions (HAPC) | ||||||||||||
End point description |
Manometry recordings were read by an experienced gastroenterologist who was blinded to the treatment each subject received. The tracings were analyzed using computer-based validated software. HAPC and manometry data were available for every sensor as well as average values for each HAPC and manometry time point. The primary outcome analysis of HAPC data used the following threshold: Mean amplitude ≥100mmHg and extension ≥20cm (9 sensors).
This end point analyzed the Pharmacodynamic Analysis Set, which consisted of all randomized subjects who had taken at least 1 dose of investigational product and who had 1 evaluable manometry assessment (minimum of 4 hours of manometry recordings from the intake of investigational product) for each treatment period.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Over 12 hours post-dose
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Analysis of HPACs | ||||||||||||
Comparison groups |
PEG 3350 v Prucalopride
|
||||||||||||
Number of subjects included in analysis |
24
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.012 | ||||||||||||
Method |
Linear Mixed-Effect Models Analysis | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
5.8
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
1.6 | ||||||||||||
upper limit |
9.9 |
|
|||||||||||||
End point title |
Area Under The Concentration Curve (AUC) of All HAPCs | ||||||||||||
End point description |
The AUC of all HAPCs during the first 12 hours after treatment was calculated as the sum of the AUC at all sensors of each HAPC at the ≥100mmHg and ≥20cm threshold.
This end point analyzed the Pharmacodynamic Analysis Set, which consisted of all randomized subjects who had taken at least 1 dose of investigational product and who had 1 evaluable manometry assessment (minimum of 4 hours of manometry recordings from the intake of investigational product) for each treatment period.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Over 12 hours post-dose
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Analysis of AUC of All HAPCs | ||||||||||||
Comparison groups |
PEG 3350 v Prucalopride
|
||||||||||||
Number of subjects included in analysis |
15
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.079 | ||||||||||||
Method |
Linear Mixed-Effect Models Analysis | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
69051.4
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-12004.5 | ||||||||||||
upper limit |
150107.3 |
|
|||||||||||||
End point title |
The Mean Amplitude of HAPC | ||||||||||||
End point description |
The mean amplitude of all HAPCs was calculated as the sum of the mean amplitude for each HAPC divided by the number of HAPCs.
This end point analyzed the Pharmacodynamic Analysis Set, which consisted of all randomized subjects who had taken at least 1 dose of investigational product and who had 1 evaluable manometry assessment (minimum of 4 hours of manometry recordings from the intake of investigational product) for each treatment period.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Over 12 hours post-dose
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Analysis of Mean Amplitude of HAPC | ||||||||||||
Comparison groups |
Prucalopride v PEG 3350
|
||||||||||||
Number of subjects included in analysis |
15
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.717 | ||||||||||||
Method |
Linear Mixed-Effect Models Analysis | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
9.2
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-45.3 | ||||||||||||
upper limit |
63.7 |
|
|||||||||
End point title |
Time to First HAPC | ||||||||
End point description |
The median (95% confidence interval) time to first HAPC after administration of investigational product with amplitude ≥100mmHg and extension ≥20cm.
This end point analyzed the Pharmacodynamic Analysis Set, which included all subjects in the Safety Analysis Set who had 1 evaluable manometry assessment (minimum of 4 hours of manometry recordings from the intake of investigational product) for each treatment period.
In the PEG 3350 group, the median time to first HAPC after administration of investigational product with amplitude ≥100mmHg and extension ≥20cm could not be calculated as only 6 subjects had HAPCs that met this threshold.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Over 12 hours post-dose
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Propagation Velocity of HAPC | ||||||||||||
End point description |
Propagation velocity was calculated as the extension divided by the duration for each HAPC. Mean propagation velocity is the sum of the propagation velocities divided by the number of HAPCs.
This end point analyzed the Pharmacodynamic Analysis Set, which consisted of all randomized subjects who had taken at least 1 dose of investigational product and who had 1 evaluable manometry assessment (minimum of 4 hours of manometry recordings from the intake of investigational product) for each treatment period.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Over 12 hours post-dose
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Analysis of Propagation Velocity of HAPC | ||||||||||||
Comparison groups |
Prucalopride v PEG 3350
|
||||||||||||
Number of subjects included in analysis |
15
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.18 | ||||||||||||
Method |
Linear Mixed-Effect Models Analysis | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
-0.179
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.465 | ||||||||||||
upper limit |
0.107 |
|
|||||||||||||
End point title |
Duration of HAPC | ||||||||||||
End point description |
The mean duration of all HAPCs was calculated as the sum of the duration of each HAPC divided by the number of HAPCs.
This end point analyzed the Pharmacodynamic Analysis Set, which consisted of all randomized subjects who had taken at least 1 dose of investigational product and who had 1 evaluable manometry assessment (minimum of 4 hours of manometry recordings from the intake of investigational product) for each treatment period.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Over 12 hours post-dose
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Analysis of Duration of HAPC | ||||||||||||
Comparison groups |
Prucalopride v PEG 3350
|
||||||||||||
Number of subjects included in analysis |
15
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.225 | ||||||||||||
Method |
Linear Mixed-Effect Models Analysis | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
15.8
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-12.6 | ||||||||||||
upper limit |
44.3 |
|
||||||||||||||||||||||
End point title |
Motility Index | |||||||||||||||||||||
End point description |
Motility index (mmHg) was summarized for the following 3 time points: pre-dose, 0-5 hours post-dose, and 5-12 hours post-dose. The motility index is defined as the natural logarithm of all peak amplitudes of every contraction +1.
This end point analyzed the Pharmacodynamic Analysis Set, which consisted of all randomized subjects who had taken at least 1 dose of investigational product and who had 1 evaluable manometry assessment (minimum of 4 hours of manometry recordings from the intake of investigational product) for each treatment period.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Over 12 hours post-dose
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Up to 35 days
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
15.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Prucalopride
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
A single dose of 2mg prucalopride, administered orally as tablets with 125mL of water on Day 1. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Polyethylene Glycol
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1 (once in the morning and once prior to lunch). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
26 Sep 2012 |
The general amendment included the following changes:
1-The medical monitor was changed
2-Due to concerns regarding the original lengthy fasting period between Day -2 and Day 1, dinner was added to Day -2 and Day -1, and an afternoon snack was added to Day -1
3-The original text on the packaging of the investigational product was corrected
4-Additional wording was added on the timing of colonic multiple sensor catheter placement
5-The original text on the reporting period for SAEs was changed from "must occur within one business day" to "must occur within 24 hours"
5-Minor editorial changes were performed |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |